IL15 and hepatocellular carcinoma: In vivo studies involving subcutaneous injection of human hepatoma cells HCC-LM9 into humanized IL15 transgenic NCG (NCG-hIL15) mice demonstrated that weekly adoptive transfer (intravenously) of shmiR155HG-NK92 cells, beginning on Day 7 post-injection, resulted in faster tumor growth and greater tumor weight compared to mice that received shCtrl-NK92 cell (Fig. 2N).